Inicio › Cáncer de mama triple negativo › Tennessee › Nashville
Ensayos clínicos de Cáncer de mama triple negativo en Nashville, TN
28 estudios para Cáncer de mama triple negativo buscan participantes en centros de Nashville y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutandoFase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- Sarah Cannon Research Institute, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
ReclutandoFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
ReclutandoFase 1
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
ReclutandoFase 1/2
- SCRI Oncology Partners, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
ReclutandoEstudio observacional
- Vanderbilt University Medical Center, Nashville
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
ReclutandoFase 3
- SCRI Oncology Partners ( Site 7004), Nashville
- Tennessee Oncology ( Site 0018), Nashville
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
ReclutandoFase 3
- One Oncology - Tennessee Oncology ( Site 0098), Nashville
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0111), Nashville
- y 1 más
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
ReclutandoFase 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
ReclutandoFase 1
- Sarah Cannon - Tennessee Oncology, Nashville
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
ReclutandoFase 1
- Sarah Cannon Research Institute, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
ReclutandoEstudio observacional
- Nashville General, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
ReclutandoFase 1
- Normunity Investigational Site, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Vanderbilt University Medical Center, Nashville
SMP-3124LP in Adults With Advanced Solid Tumors
ReclutandoFase 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
ReclutandoFase 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
ReclutandoFase 1
- Tennessee Oncology, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
ReclutandoFase 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
ReclutandoFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
ReclutandoFase 1
- Sarah Cannon Research Institute, Nashville
Study of XB010 in Subjects With Solid Tumors
ReclutandoFase 1
- SCRI Oncology Partners, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
ReclutandoFase 1
- SCRI Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Reclutando
- Vanderbilt-Ingram Cancer Center, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
ReclutandoFase 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
ReclutandoFase 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
ReclutandoFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
ReclutandoFase 2
- SCRI Oncology Partners, Nashville
Ensayos de Cáncer de mama triple negativo en otras ciudades
- Houston, TX42 estudios
- New York City, NY31 estudios
- Los Angeles, CA27 estudios
- Boston, MA26 estudios
- San Antonio, TX23 estudios
- St. Louis, MO21 estudios
- Arlington, VA20 estudios
- Atlanta, GA20 estudios
- Dallas, TX18 estudios
- Chicago, IL16 estudios
- Columbus, OH16 estudios
- Grand Rapids, MI15 estudios
Otros estudios en Nashville
- Cáncer de pulmón de células no pequeñas97 estudios
- Cáncer de seno81 estudios
- Cáncer metastásico70 estudios
- Cáncer del colon y del recto69 estudios
- Cáncer (todos los tipos)65 estudios
- Cáncer de ovario49 estudios
- Cáncer de próstata43 estudios
- Cáncer de pulmón40 estudios
- Carcinoma de células escamosas de cabeza y cuello39 estudios
- Cáncer de páncreas39 estudios
- Cáncer de endometrio38 estudios
- Melanoma33 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.